Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Equity Average (2018 - 2025)

Inmune Bio's Equity Average history spans 8 years, with the latest figure at $27.1 million for Q3 2025.

  • For Q3 2025, Equity Average fell 27.63% year-over-year to $27.1 million; the TTM value through Sep 2025 reached $27.1 million, down 27.63%, while the annual FY2024 figure was $34.7 million, 28.74% down from the prior year.
  • Equity Average for Q3 2025 was $27.1 million at Inmune Bio, down from $29.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $84.2 million in Q4 2021 and bottomed at $27.1 million in Q3 2025.
  • The 5-year median for Equity Average is $51.2 million (2021), against an average of $50.4 million.
  • The largest annual shift saw Equity Average surged 142.21% in 2021 before it plummeted 43.19% in 2024.
  • A 5-year view of Equity Average shows it stood at $84.2 million in 2021, then decreased by 26.51% to $61.9 million in 2022, then plummeted by 34.36% to $40.6 million in 2023, then fell by 12.92% to $35.4 million in 2024, then decreased by 23.35% to $27.1 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Equity Average are $27.1 million (Q3 2025), $29.3 million (Q2 2025), and $30.9 million (Q1 2025).